|Articles|May 2, 2019

Pharmaceutical Technology

  • Pharmaceutical Technology-05-02-2019
  • Volume 43
  • Issue 5

New Kit Identifies Endonuclease Impurities

The EndonucleaseGTP ELISA Kit from Cygnus Technologies detects and quantitates residual endonuclease impurities in recombinant vaccines and viral vectors used for gene therapy.

The EndonucleaseGTP ELISA Kit from Cygnus Technologies detects and quantitates residual endonuclease impurities in recombinant vaccines and viral vectors used for gene therapy. With a detection limit of ~0.06 ng/mL, the kit is three times more sensitive than the only other commercially available assay for detection and quantitation of these endonuclease impurities, according to the company. The kit also contains all the necessary, ready-to-use reagents for 96 analyses in microplate format, including a set of calibrated endonuclease standards. The assay can be easily integrated into desired workflow points-from process development to quality control to lot release testing.

Cygnus Technologies

Articles in this issue

over 6 years ago

Contract Packaging Grows

over 6 years ago

New Pneumatic Presses

over 6 years ago

New Size for AODD Pump

over 6 years ago

The Auditor Vs. Inspector Issue

over 6 years ago

Avoiding Excipient Variability

over 6 years ago

Working for the Greater Good

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.